Atrix Names Dr. Charles P. Cox Senior Vice President Corporate Development

Apr 30, 2001, 01:00 ET from Atrix Laboratories, Inc.

    FORT COLLINS, Colo., April 30 /PRNewswire/ -- Atrix Laboratories, Inc.
 (Nasdaq:   ATRX) announced today the promotion of Charles P. Cox, Ph.D. MBA to
 the position of senior vice president of corporate development.
     "Charlie has been an integral part of the Atrix executive management team
 since 1992, first serving as vice president of product development and more
 recently as vice president of new business development," said David R.
 Bethune, Atrix chairman and chief executive officer.  "Charlie plays a
 critical role in all of our strategic alliances including Elan, Pfizer,
 Sanofi-Synthelabo and MediGene.  We are very pleased to have him serve in the
 new role as senior vice president of corporate development."
     Dr. Cox holds a Ph.D. in Medical Microbiology and Immunology from the
 University of Oklahoma Health Sciences Center and a Masters of Business
 Administration from the J. L. Kellogg Graduate School of Management at
 Northwestern University.  Prior to joining Atrix, he was director of project
 management at G.D. Searle & Company.  Dr. Cox is a member of the American
 Association of Immunologists, the American Thoracic Society and the Licensing
 Executives Society.
 
     ABOUT ATRIX LABORATORIES
     Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company
 focused on advanced drug delivery.  With five unique patented technologies,
 Atrix is currently developing a diverse portfolio of proprietary products,
 including oncology, pain management, and dermatology products.  The company
 also partners with large pharmaceutical and biotechnology companies to apply
 its proprietary technologies to new chemical entities or to extend the patent
 life of existing products.  Atrix has strategic alliances with several
 pharmaceutical companies including recent collaborations with Pfizer, Elan
 Corporation Plc, Sanofi-Synthelabo, MediGene and the Novartis company - Geneva
 Pharmaceuticals, to use its drug delivery technologies and expertise in the
 development of new products.  Additional information is available on the Atrix
 Laboratories, Inc. Web site at http://www.atrixlabs.com.
 
     Statements contained in this press release, which are not historical
 facts, are forward-looking statements, as the term is defined in the Private
 Securities Litigation Reform Act of 1995.  Such forward-looking statements are
 subject to risks and uncertainties which can cause actual results to differ
 materially from those currently anticipated, due to a number of factors, which
 include, but are not limited to, product demand, pricing, market acceptance,
 changing economic conditions, risks in product and technology development, the
 effect of the company's accounting policies and other risk factors discussed
 in documents filed by the company with the Securities and Exchange Commission
 from time to time.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X60651592
 
 

SOURCE Atrix Laboratories, Inc.
    FORT COLLINS, Colo., April 30 /PRNewswire/ -- Atrix Laboratories, Inc.
 (Nasdaq:   ATRX) announced today the promotion of Charles P. Cox, Ph.D. MBA to
 the position of senior vice president of corporate development.
     "Charlie has been an integral part of the Atrix executive management team
 since 1992, first serving as vice president of product development and more
 recently as vice president of new business development," said David R.
 Bethune, Atrix chairman and chief executive officer.  "Charlie plays a
 critical role in all of our strategic alliances including Elan, Pfizer,
 Sanofi-Synthelabo and MediGene.  We are very pleased to have him serve in the
 new role as senior vice president of corporate development."
     Dr. Cox holds a Ph.D. in Medical Microbiology and Immunology from the
 University of Oklahoma Health Sciences Center and a Masters of Business
 Administration from the J. L. Kellogg Graduate School of Management at
 Northwestern University.  Prior to joining Atrix, he was director of project
 management at G.D. Searle & Company.  Dr. Cox is a member of the American
 Association of Immunologists, the American Thoracic Society and the Licensing
 Executives Society.
 
     ABOUT ATRIX LABORATORIES
     Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company
 focused on advanced drug delivery.  With five unique patented technologies,
 Atrix is currently developing a diverse portfolio of proprietary products,
 including oncology, pain management, and dermatology products.  The company
 also partners with large pharmaceutical and biotechnology companies to apply
 its proprietary technologies to new chemical entities or to extend the patent
 life of existing products.  Atrix has strategic alliances with several
 pharmaceutical companies including recent collaborations with Pfizer, Elan
 Corporation Plc, Sanofi-Synthelabo, MediGene and the Novartis company - Geneva
 Pharmaceuticals, to use its drug delivery technologies and expertise in the
 development of new products.  Additional information is available on the Atrix
 Laboratories, Inc. Web site at http://www.atrixlabs.com.
 
     Statements contained in this press release, which are not historical
 facts, are forward-looking statements, as the term is defined in the Private
 Securities Litigation Reform Act of 1995.  Such forward-looking statements are
 subject to risks and uncertainties which can cause actual results to differ
 materially from those currently anticipated, due to a number of factors, which
 include, but are not limited to, product demand, pricing, market acceptance,
 changing economic conditions, risks in product and technology development, the
 effect of the company's accounting policies and other risk factors discussed
 in documents filed by the company with the Securities and Exchange Commission
 from time to time.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X60651592
 
 SOURCE  Atrix Laboratories, Inc.